As for those with hyperglycemia with or without hypertension at baseline, relacorilant significantly improved fasting glucose ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

Hypertension, diabetes, obesity and having unhealthy diets are blamed for the alarming rise of the diseases. Some other ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

A new study examining hypertension medication adherence found that high-tech interventions failed to improve how consistently patients take their blood pressure medications, despite successfully ...

Delayed diagnosis of hypertension after initial elevated BP measurement was tied to lower rates of antihypertensive drug ...

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...